Inpatient and final histologic results
| Hospitalization time [Mean±SD (Range)]; day | 3.7±1.1 (2–6) |
| Complications (Clavien–Dindo); n(%) | |
| Grade I | 0 (0) |
| Grade II | 1 (5) |
| Grade III | 1 (5) |
| Grade IV | 0 (0) |
| Grade V | 0 (0) |
| Adverse events related with 99mTC or ICG use (<30 days); n (%) | 0 (0) |
| Histotype; n (%) | |
| Serous | 4 (20) |
| Endometrioid | 8 (40) |
| Mucinous | 2 (10) |
| Clear cells | 5 (25) |
| Other | 1 (5) |
| Grade; n (%) | |
| G1 | 8 (40) |
| G2 | 0 (0) |
| G3 | 11 (55) |
| Not applicable (disgerminoma) | 1 (5) |
| ILV; n (%) | 0 (0) |
| FIGO stage; n (%) | |
| IA | 7 (35) |
| IC | 11 (55) |
| IIA | 1 (5) |
| IIIB | 1 (5) |
| Pelvic LND [Mean±SD (Range)]; nodes | 20.1±7.6 (9–74) |
| Para-aortic LND [Mean±SD (Range)]; nodes | 19.8±10.4 (6–40) |
| Pelvic SLN removed [Mean±SD (Range)]; nodes | 2.2±1.5 (0–5) |
| Para-aortic SLN removed [Mean±SD (Range)]; nodes | 3.3±1.8 (1–7) |
FIGO, The International Federation of Gynecology and Obstetrics; ICG, Indocyanine green; LND, lymphadenectomy; LVI, lymph vascular invasion; SLN, sentinel lymph node.